Seventeen pharmaceutical manufacturers covering about 86 percent of the branded drug market have signed the Trump administration’s most-favored-nation pricing agreements, but the framework splits into two different obligations depending on when a drug reached the market. Every new drug those companies launch must carry a U.S. list price tied to the lowest price charged in other wealthy nations, applied across every kind of coverage, from employer insurance to Medicare. Drugs already sitting on pharmacy shelves face a narrower rule: the matching discount is guaranteed only inside state Medicaid programs. That distinction, buried under the 86 percent headline, is worth tens of billions of dollars and decides whether a given prescription actually gets cheaper.
A Split Deal: New Launches and Existing Drugs Play by Different Rules
The 86 percent figure comes from a White House accounting of the branded pharmaceutical market covered by the seventeen manufacturers now under agreement, a group the administration describes as including most of the largest sellers of patent-protected medicines in the country. Under what the administration calls prospective most-favored-nation pricing, those companies must price every newly launched drug in the United States at a level comparable to what they charge in other high-income countries, a commitment that reaches private insurance, employer plans and Medicare simultaneously rather than one payer at a time. The administration’s own research office projects that provision alone will generate $529 billion in domestic savings over the next ten years, the largest single component of the entire framework.
Drugs that were already on the market before the agreements took effect operate under a separate, more limited commitment. For those existing drugs, manufacturers are required to extend most-favored-nation pricing specifically to state Medicaid programs, not to commercial insurers or to Medicare’s standard drug benefit, which continue to pay through their own separate pricing channels. The administration’s report puts the ten-year value of that narrower Medicaid guarantee at $64.3 billion in combined federal and state savings, a fraction of the prospective-drug total but a direct line item in the budgets that fund care for low-income seniors and people with disabilities.
The administration has also acknowledged that the seventeen-company roster is not the finish line. The White House’s own release describes the agreements as covering roughly 86 percent of the branded market, and its research office states it expects to reach similar agreements with most manufacturers of sole-source brand-name drugs and biologics still outside the framework, meaning a portion of patented medicines remain untouched by any most-favored-nation commitment while company-by-company negotiations continue.
Free retirement updates: Want plain-English help keeping more of your money in retirement? The free Retirement Shield newsletter covers the benefits, deadlines, and money mistakes that cost retirees, a couple times a week. Subscribe free.
What the Direct Channel Saves, and Who It Doesn’t Reach
Beyond the market-wide pricing rules, the most-favored-nation deals also feed TrumpRx.gov, the administration’s direct-to-consumer ordering platform, where the savings are pitched in dollar terms rather than percentages. The administration’s research office estimates that a person without insurance coverage who fills a GLP-1 prescription through the platform will save about $3,000 a year compared with the prior list price, and that a couple paying out of pocket for fertility medication could save more than $6,000 over a treatment cycle.
Those figures apply specifically to patients paying cash, a group that includes people whose plans exclude a drug, people between insurance plans, and Medicare beneficiaries whose Part D coverage does not extend to a particular use of a medication. A retiree with a standard Medicare drug plan that already covers a prescription is paying a copay set by that plan’s formulary, not the list price the most-favored-nation deal is designed to undercut, so the size of any personal savings depends heavily on whether coverage already exists for that specific drug and use.
The administration has tied part of its Medicare strategy to the same price reductions, framing the lower costs it secured for GLP-1 drugs as what makes an eventual expansion of Medicare coverage for anti-obesity treatment fiscally workable. That framing links the seventeen-company agreement directly to a benefit question for older beneficiaries: whether the federal government can afford to add a category of drugs to Medicare’s covered list without the price concessions the administration says it has already extracted from manufacturers.
The Deductible Bill Still Sitting in Committee
A gap remains for insured patients who might otherwise use TrumpRx to capture a lower price: money spent on the platform generally does not count toward a health plan’s annual deductible or out-of-pocket maximum, because those totals are normally built from claims an insurer processes, not cash purchases made outside the plan. Legislation introduced in the U.S. House in April, H.R. 8270, the Every Dollar Counts Act of 2026, would require insurers to count out-of-pocket drug spending toward those limits regardless of where a patient bought the medication, but the bill remains in committee and has not reached a floor vote.
Without that fix, an insured patient who pays the lower TrumpRx price for a drug still has to separately spend toward a deductible through the normal insurance channel before coverage applies, which reduces the incentive to shop on the cash-pay platform even when its listed price beats an insurer’s negotiated rate. The administration’s research office lists the fix as part of a broader agenda rather than something already secured, describing it only as legislation the administration is working with Congress to advance.
That distinction points to the larger unresolved piece of the agreement: the price commitments from the seventeen manufacturers are voluntary arrangements the companies made directly with the administration, not requirements written into federal statute. The administration’s research office states it is separately working with Congress to codify those voluntary agreements into law so patients continue benefiting from the price discounts, language that concedes the current 86 percent figure rests on commitments a future administration, or the companies themselves, could unwind without a change in the law.
This article was researched and drafted with the assistance of artificial intelligence.
More Financial Reading
